Johnny Mahlangu to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Johnny Mahlangu has written about Antibodies, Monoclonal, Humanized.
Connection Strength
5,091
-
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Expert Rev Hematol. 2024 Oct; 17(10):741-748.
Score: 0,871
-
Emicizumab for the prevention of bleeds in hemophilia A. Expert Opin Biol Ther. 2019 08; 19(8):753-761.
Score: 0,605
-
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
Score: 0,583
-
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
Score: 0,573
-
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
Score: 0,203
-
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248.
Score: 0,191
-
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 01; 200(2):229-239.
Score: 0,189
-
Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
Score: 0,185
-
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
Score: 0,172
-
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228.
Score: 0,169
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
Score: 0,169
-
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
Score: 0,169
-
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
Score: 0,166
-
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
Score: 0,164
-
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
Score: 0,157
-
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
Score: 0,145
-
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
Score: 0,132
-
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
Score: 0,113
-
A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022 04 28; 139(17):2642-2652.
Score: 0,046
-
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
Score: 0,044
-
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
Score: 0,044